KRAS and cancer: The pathway may be activated by cytokines and growth factors secreted by CAFs, such as COX2 (PTGS2)/PEG2 (PTGER2) [42] or IL6 which were up‐regulated in PM CMS4, or through pathway‐related genetic mutations in the cancer cells, such as KRAS mutations [40].